fashion -WSS

fashion

author：leisure time 2025-10-01 04:10:00 - browse：34871

Monica Bertagnolli -- Health Policy coverage from STAT — Dr. Monica Bertagnolli speaks during a visit from first lady Jill Biden to the University of California San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, Friday, Oct. 7, 2022. (AP Photo/Jeff Chiu, Pool) Jeff Chiu/AP

WASHINGTON — Sen. Bernie Sanders (I-Vt.) will hold a confirmation hearing next month for Monica Bertagnolli, President Biden’s nominee to run the National Institutes of Health, he said Friday.

Sanders, whose health committee oversees the confirmation of the NIH nominee, had refused to hold a hearing on Bertagnolli until the Biden administration promised more drug pricing reform.

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care.

Please enter a valid email address. Privacy Policy

HHS announced Friday a deal with Regeneron on the development of the Covid-19 monoclonal antibody. That deal seems to have satisfied Sanders’ demands, though Sanders said the administration must add reasonable pricing provisions to all drugs developed with the help of government funding.

“I welcome the Biden Administration’s announcement today that if Regeneron, through a $326 million contract recently signed with HHS, successfully develops a next generation monoclonal antibody for Covid-19 prevention, the list price of this drug must be equal to or lower than the price in other major countries,” Sanders said in a release.

Sen. Elizabeth Warren (D-Mass.) also had withheld support for Bertagnolli’s nomination until Bertagnolli agreed to Warren’s ethics demands. Bertagnolli agreed to not join the pharmaceutical industry or accept payment from the drug industry, until at least four years after leaving her government position.

Previous article： How to save PrEP access — and even expand it
Next article： FDA authorizes Novavax’s updated Covid

focus

explore

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Phenylephrine and the overlooked value of the placebo effect

U.K. officials, researchers try to ease path for bespoke genetic treatments

Colorectal cancer study finds potential in overlooked immune cell

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

This gene therapy has record $4.25 million price. It's saved children.

focus

fashion

Sign up for D.C. Diagnosis

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

Medical devices makers are asking for forgiveness, not permission

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why Charlie Gard's case is so disturbing to Americans

Novavax promises a turnaround & Lilly roils the obesity market

Chan Zuckerberg Biohub Chicago to focus on inflammation

Psychedelics group wrestles with new pharma identity

6 surprising facts about sugar

At least 13 dead in Texas as scorching temps continue

Bill would stop addiction treatment from triggering child abuse inquiry

entertainment

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Asbestos ban is immediate, but health effects will linger for decades

Medical devices makers are asking for forgiveness, not permission

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Yancopoulos of Regeneron works to expand Dupixent success

Cancer, immunology, HIV research ensnared in fetal tissue politics

focus

leisure time

explore

leisure time